TY  - JOUR
AU  - Kostadinović, Jelena
AU  - Popadić, Višeslav
AU  - Klašnja, Slobodan
AU  - Klisić, Aleksandra
AU  - Kotur-Stevuljević, Jelena
AU  - Andrić, Zoran
AU  - Zdravković, Marija
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4629
AB  - The clinical efficacy of chemotherapy, as a recognized therapeutic approach for malignant 
diseases,   usually   has   certain   limitations   due   to   its   cardiotoxicity   (CT)   and   consequent   
cardiomyopathy,  or  even  heart  failure.  CT
  is  defined  as  any  cardiac  injury  connected  with  
oncology treatment, whether it is chemo
-, radio
-, targeted or immunotherapy, or cancer by itself, 
and it represents a great challenge for clinicians in everyday practice. A wide spectrum of factors 
related t
o chemotherapy (type of drug, dose during each cycle, cumulative dose, schedule, method 
of  application,  combination  with  other  cardiotoxic  drugs  or  association  with  radiotherapy)  and  
patient  characteristics  (age,  presence  of  cardiovascular  risk  factors,  pr
evious  cardiovascular  
disease)  are  the  determining  factors  that  influence  the  frequency  of  CT.  Imaging  methods  for  
morphological  and  functional  monitoring  of  the  heart  muscle  are  used  for  monitoring  CT.  The  
quest  for  diagnostic  tools  for  early  CT  detection 
is  of  great  significance.  In  line  with  this,  the  
measurement  of  some  cardiac  biomarkers  has  found  its  place  in  clinical  settings  as  an  early  
determinant of myocardial injury. Therefore, in this review article, special attention will be paid 
to  certain  wel
l-established,  as  well  as  certain  novel  cardiac  biomarkers,  and  their  role  in  
recognizing asymptomatic CT, in order to gain deeper insight into their diagnostic utility.
AB  - Klinička  efikasnost  hemioterapije,  kao  priznatog  terapeutskog  pristupa  malignim 
bolestima, obično ima određena ograničenja zbog svoje kardiotoksičnosti (KT), te posledične 
kardiomiopatije, pa čak i srčane insuficijencije. KT se definiše kao svaka povreda miokarda 
povezana  s  lečenjem  raka,  uzimajući  u  obzir  hemioterapiju,  radioterapiju,  biološku  ili 
imunoterapiju,  kao  i  sam  karcinom,  te  predstavlja veliki  izazov  za  kliničare 
u  svakodnevnoj  
praksi. Širok spektar faktora povezanih s hemioterapijom (vrsta leka, doza tokom svakog ciklusa, 
kumulativna doza, raspored, način primene, kombinacija s drugim kardiotoksičnim lekovima ili 
povezanost s radioterapijom) i karakteristike bolesnika (dob, prisutnost faktora kardiovaskularnog 
rizika, prethodne kardiovaskularne bolesti), odlučujući su faktori koji utiču na učestalost KT. Za 
praćenje KT koriste se radiološke metode za morfološko i funkcionalno praćenje srčanog mišića. 
Potraga za dij
agnostičkim alatima za rano otkrivanje KT od velikog je značaja. U skladu s tim, 
merenje nekih srčanih biomarkera kao rane determinante povrede miokarda našlo je svoje mesto 
u kliničkim okruženjima. Stoga 
će u ovom preglednom članku posebna pažnja biti po
sve
ć
ena 
nekim  dobro  utvrđenim,  kao  i  nekim  novim  srčanim  biomarkerima,  i  njihovoj  ulozi  u 
prepoznavanju asimptomatske KT, kako bi se stekao dublji uvid u njihovu dijagnostičku korisnost 
i neželjene efekte lekova koji se primenjuju u terapiji karcinoma.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
T2  - Arhiv za farmaciju
T1  - Cardiotoxicity: Importance of biomarkers
T1  - Kardiotoksičnost: Važnost biomarkera
VL  - 73
IS  - 1
SP  - 1
EP  - 16
DO  - 10.5937/arhfarm73-40534
ER  - 

@article{
author = "Kostadinović, Jelena and Popadić, Višeslav and Klašnja, Slobodan and Klisić, Aleksandra and Kotur-Stevuljević, Jelena and Andrić, Zoran and Zdravković, Marija",
year = "2023",
abstract = "The clinical efficacy of chemotherapy, as a recognized therapeutic approach for malignant 
diseases,   usually   has   certain   limitations   due   to   its   cardiotoxicity   (CT)   and   consequent   
cardiomyopathy,  or  even  heart  failure.  CT
  is  defined  as  any  cardiac  injury  connected  with  
oncology treatment, whether it is chemo
-, radio
-, targeted or immunotherapy, or cancer by itself, 
and it represents a great challenge for clinicians in everyday practice. A wide spectrum of factors 
related t
o chemotherapy (type of drug, dose during each cycle, cumulative dose, schedule, method 
of  application,  combination  with  other  cardiotoxic  drugs  or  association  with  radiotherapy)  and  
patient  characteristics  (age,  presence  of  cardiovascular  risk  factors,  pr
evious  cardiovascular  
disease)  are  the  determining  factors  that  influence  the  frequency  of  CT.  Imaging  methods  for  
morphological  and  functional  monitoring  of  the  heart  muscle  are  used  for  monitoring  CT.  The  
quest  for  diagnostic  tools  for  early  CT  detection 
is  of  great  significance.  In  line  with  this,  the  
measurement  of  some  cardiac  biomarkers  has  found  its  place  in  clinical  settings  as  an  early  
determinant of myocardial injury. Therefore, in this review article, special attention will be paid 
to  certain  wel
l-established,  as  well  as  certain  novel  cardiac  biomarkers,  and  their  role  in  
recognizing asymptomatic CT, in order to gain deeper insight into their diagnostic utility., Klinička  efikasnost  hemioterapije,  kao  priznatog  terapeutskog  pristupa  malignim 
bolestima, obično ima određena ograničenja zbog svoje kardiotoksičnosti (KT), te posledične 
kardiomiopatije, pa čak i srčane insuficijencije. KT se definiše kao svaka povreda miokarda 
povezana  s  lečenjem  raka,  uzimajući  u  obzir  hemioterapiju,  radioterapiju,  biološku  ili 
imunoterapiju,  kao  i  sam  karcinom,  te  predstavlja veliki  izazov  za  kliničare 
u  svakodnevnoj  
praksi. Širok spektar faktora povezanih s hemioterapijom (vrsta leka, doza tokom svakog ciklusa, 
kumulativna doza, raspored, način primene, kombinacija s drugim kardiotoksičnim lekovima ili 
povezanost s radioterapijom) i karakteristike bolesnika (dob, prisutnost faktora kardiovaskularnog 
rizika, prethodne kardiovaskularne bolesti), odlučujući su faktori koji utiču na učestalost KT. Za 
praćenje KT koriste se radiološke metode za morfološko i funkcionalno praćenje srčanog mišića. 
Potraga za dij
agnostičkim alatima za rano otkrivanje KT od velikog je značaja. U skladu s tim, 
merenje nekih srčanih biomarkera kao rane determinante povrede miokarda našlo je svoje mesto 
u kliničkim okruženjima. Stoga 
će u ovom preglednom članku posebna pažnja biti po
sve
ć
ena 
nekim  dobro  utvrđenim,  kao  i  nekim  novim  srčanim  biomarkerima,  i  njihovoj  ulozi  u 
prepoznavanju asimptomatske KT, kako bi se stekao dublji uvid u njihovu dijagnostičku korisnost 
i neželjene efekte lekova koji se primenjuju u terapiji karcinoma.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Cardiotoxicity: Importance of biomarkers, Kardiotoksičnost: Važnost biomarkera",
volume = "73",
number = "1",
pages = "1-16",
doi = "10.5937/arhfarm73-40534"
}

Kostadinović, J., Popadić, V., Klašnja, S., Klisić, A., Kotur-Stevuljević, J., Andrić, Z.,& Zdravković, M.. (2023). Cardiotoxicity: Importance of biomarkers. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 73(1), 1-16.
https://doi.org/10.5937/arhfarm73-40534

Kostadinović J, Popadić V, Klašnja S, Klisić A, Kotur-Stevuljević J, Andrić Z, Zdravković M. Cardiotoxicity: Importance of biomarkers. in Arhiv za farmaciju. 2023;73(1):1-16.
doi:10.5937/arhfarm73-40534 .

Kostadinović, Jelena, Popadić, Višeslav, Klašnja, Slobodan, Klisić, Aleksandra, Kotur-Stevuljević, Jelena, Andrić, Zoran, Zdravković, Marija, "Cardiotoxicity: Importance of biomarkers" in Arhiv za farmaciju, 73, no. 1 (2023):1-16,
https://doi.org/10.5937/arhfarm73-40534 . .

TY  - JOUR
AU  - Kostadinović, Jelena
AU  - Kotur-Stevuljević, Jelena
AU  - Ivanović, Nevena
AU  - Andrić, Zoran
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5374
AB  - Malnutrition as a consequence of the disease occurs most
often in cancer patients, not only because of the cancer
itself, but also because of the oncological treatment. The
most important cause is chemotherapy, followed by ra-
diotherapy and onco-surgery. Therefore, efforts are being
made all over the world to find different ways to solve this
difficult medical problem. Given that the mechanism of
malnutrition caused by cancer is not sufficiently elucidat-
ed, the efforts made to design an adequate approach and
treatment of this disorder are often unsuccessful. In order
to improve the nutritional status of oncology patients, their
nutritional disorder should be adequately diagnosed and
then specific measurements should be performed (deter-
mination of body composition, the proportion of water, fat,
muscle, as well as the determination of various biomarkers
in the blood, for example markers inflammation). In this way, it is possible to formulate a multimodal approach to the
treatment of malnutrition in oncology patients, which would include the intake of adequate foods, increased physical
activity and personalized supplementation.
AB  - Pothranjenost kao posledica bolesti se najčešće javlja kod
onkoloških pacijenata i to ne samo zbog samog kancera,
već i zbog onkološkog lečenja. Najznačajniji uzročnik je
hemioterapija, potom radioterapija i onko-hirurgija. Zbog
toga se širom sveta ulažu napori i pronalaze različiti načini
za rešavanje ovog teškog medicinskog problema. S obzirom
na to da mehanizam nastanka pothranjenosti uzrokovane
karcinomom nije dovoljno rasvetljen, napori koji se ulažu
da se osmisli adekvatan pristup i tretman ovog poremećaja se često neuspešno završe. Da bi se nutritivni status onko-
loških pacijenata popravio njima pre svega treba da bude dijagnostikovan nutritivni poremećaj, a zatim da se sprovedu
specifična merenja (određivanje sastava tela, udeo vode, masti, mišića, kao i da se u krvi odrede različiti biomarkeri, na
primer markeri zapaljenja). Na taj način je moguće formulisati multimodalni pristup u lečenju pothranjenosti onkoloških
bolesnika koji bi obuhvatio unos adekvatnih namirnica, povećanje fizičke aktivnosti i personalizovanu suplementaciju.
PB  - Društvo za ishranu Srbije, Beograd
T2  - Hrana i ishrana
T1  - Malnutrition induced by cancer and oncology treatment
T1  - Malnutricija uzrokovana karcinomom i onkološkom terapijom
VL  - 63
IS  - 1
SP  - 9
EP  - 16
DO  - 10.5937/hraIsh2201009K
ER  - 

@article{
author = "Kostadinović, Jelena and Kotur-Stevuljević, Jelena and Ivanović, Nevena and Andrić, Zoran",
year = "2022",
abstract = "Malnutrition as a consequence of the disease occurs most
often in cancer patients, not only because of the cancer
itself, but also because of the oncological treatment. The
most important cause is chemotherapy, followed by ra-
diotherapy and onco-surgery. Therefore, efforts are being
made all over the world to find different ways to solve this
difficult medical problem. Given that the mechanism of
malnutrition caused by cancer is not sufficiently elucidat-
ed, the efforts made to design an adequate approach and
treatment of this disorder are often unsuccessful. In order
to improve the nutritional status of oncology patients, their
nutritional disorder should be adequately diagnosed and
then specific measurements should be performed (deter-
mination of body composition, the proportion of water, fat,
muscle, as well as the determination of various biomarkers
in the blood, for example markers inflammation). In this way, it is possible to formulate a multimodal approach to the
treatment of malnutrition in oncology patients, which would include the intake of adequate foods, increased physical
activity and personalized supplementation., Pothranjenost kao posledica bolesti se najčešće javlja kod
onkoloških pacijenata i to ne samo zbog samog kancera,
već i zbog onkološkog lečenja. Najznačajniji uzročnik je
hemioterapija, potom radioterapija i onko-hirurgija. Zbog
toga se širom sveta ulažu napori i pronalaze različiti načini
za rešavanje ovog teškog medicinskog problema. S obzirom
na to da mehanizam nastanka pothranjenosti uzrokovane
karcinomom nije dovoljno rasvetljen, napori koji se ulažu
da se osmisli adekvatan pristup i tretman ovog poremećaja se često neuspešno završe. Da bi se nutritivni status onko-
loških pacijenata popravio njima pre svega treba da bude dijagnostikovan nutritivni poremećaj, a zatim da se sprovedu
specifična merenja (određivanje sastava tela, udeo vode, masti, mišića, kao i da se u krvi odrede različiti biomarkeri, na
primer markeri zapaljenja). Na taj način je moguće formulisati multimodalni pristup u lečenju pothranjenosti onkoloških
bolesnika koji bi obuhvatio unos adekvatnih namirnica, povećanje fizičke aktivnosti i personalizovanu suplementaciju.",
publisher = "Društvo za ishranu Srbije, Beograd",
journal = "Hrana i ishrana",
title = "Malnutrition induced by cancer and oncology treatment, Malnutricija uzrokovana karcinomom i onkološkom terapijom",
volume = "63",
number = "1",
pages = "9-16",
doi = "10.5937/hraIsh2201009K"
}

Kostadinović, J., Kotur-Stevuljević, J., Ivanović, N.,& Andrić, Z.. (2022). Malnutrition induced by cancer and oncology treatment. in Hrana i ishrana
Društvo za ishranu Srbije, Beograd., 63(1), 9-16.
https://doi.org/10.5937/hraIsh2201009K

Kostadinović J, Kotur-Stevuljević J, Ivanović N, Andrić Z. Malnutrition induced by cancer and oncology treatment. in Hrana i ishrana. 2022;63(1):9-16.
doi:10.5937/hraIsh2201009K .

Kostadinović, Jelena, Kotur-Stevuljević, Jelena, Ivanović, Nevena, Andrić, Zoran, "Malnutrition induced by cancer and oncology treatment" in Hrana i ishrana, 63, no. 1 (2022):9-16,
https://doi.org/10.5937/hraIsh2201009K . .

TY  - JOUR
AU  - Perović-Blagojević, Iva
AU  - Vekić, Jelena
AU  - Macut, Đuro
AU  - Ignjatović, Svetlana
AU  - Miljković-Trailović, Milica
AU  - Zeljković, Aleksandra
AU  - Spasojević-Kalimanovska, Vesna
AU  - Božić-Antić, Ivana
AU  - Bjekić-Macut, Jelica
AU  - Kastratović-Kotlica, Biljana
AU  - Andrić, Zoran
AU  - Ilić, Dušan
AU  - Kotur-Stevuljević, Jelena
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3976
AB  - Objective: Polycystic ovary syndrome (PCOS) is associated with altered lipid profile and increased small, dense LDL particles (sdLDL). Considering that paraoxonase 1 (PON1) is an anti-oxidative enzyme located on high-density lipoprotein (HDL) particles, the aim of this study was to investigate the connection between oxidative stress (OS) and PON1 activity with lipoprotein subclasses in PCOS depending on obesity. Methods: In 115 PCOS patients lipoprotein subclasses distributions were determined by gradient gel electrophoresis. OS status was assessed by total oxidative status (TOS), advanced oxidation protein products (AOPP), malondialdehyde (MDA), prooxidant-Antioxidant balance (PAB), total antioxidant status (TAS) and superoxide dismutase (SOD) and PON1 activity. Results: Overweight/obese PCOS patients (n=55) had increased OS compared to normal weight patients (n=60). In addition, overweight/obese group had lower HDL size and higher proportion of HDL 3a subclasses (P<0.05). PAB was in negative correlation with HDL 2a (P<0.001), whereas MDA and SOD correlated positively with HDL 3 subclasses (P<0.05). Serum PON1 activity was positively associated with proportions of PON1 activity on HDL 2b (P<0.05) and 2a (P<0.01), but negatively with the proportion on HDL 3 particles (P<0.01). LDL B phenotype patients had increased TAS, SOD and PON1 activity on HDL 2b, but decreased PON1 activity on HDL 3 subclasses. Conclusion: OS is associated with altered lipoprotein subclasses distribution in PCOS patients. Obesity in PCOS affects the profile of HDL subclasses, reflected through the reduced proportion of PON1 activity on HDL 3 subclasses in the presence of sdLDL particles.
PB  - Cambridge University Press
T2  - British Journal of Nutrition
T1  - Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia
VL  - 128
IS  - 4
SP  - 604
EP  - 612
DO  - 10.1017/S0007114521003585
ER  - 

@article{
author = "Perović-Blagojević, Iva and Vekić, Jelena and Macut, Đuro and Ignjatović, Svetlana and Miljković-Trailović, Milica and Zeljković, Aleksandra and Spasojević-Kalimanovska, Vesna and Božić-Antić, Ivana and Bjekić-Macut, Jelica and Kastratović-Kotlica, Biljana and Andrić, Zoran and Ilić, Dušan and Kotur-Stevuljević, Jelena",
year = "2022",
abstract = "Objective: Polycystic ovary syndrome (PCOS) is associated with altered lipid profile and increased small, dense LDL particles (sdLDL). Considering that paraoxonase 1 (PON1) is an anti-oxidative enzyme located on high-density lipoprotein (HDL) particles, the aim of this study was to investigate the connection between oxidative stress (OS) and PON1 activity with lipoprotein subclasses in PCOS depending on obesity. Methods: In 115 PCOS patients lipoprotein subclasses distributions were determined by gradient gel electrophoresis. OS status was assessed by total oxidative status (TOS), advanced oxidation protein products (AOPP), malondialdehyde (MDA), prooxidant-Antioxidant balance (PAB), total antioxidant status (TAS) and superoxide dismutase (SOD) and PON1 activity. Results: Overweight/obese PCOS patients (n=55) had increased OS compared to normal weight patients (n=60). In addition, overweight/obese group had lower HDL size and higher proportion of HDL 3a subclasses (P<0.05). PAB was in negative correlation with HDL 2a (P<0.001), whereas MDA and SOD correlated positively with HDL 3 subclasses (P<0.05). Serum PON1 activity was positively associated with proportions of PON1 activity on HDL 2b (P<0.05) and 2a (P<0.01), but negatively with the proportion on HDL 3 particles (P<0.01). LDL B phenotype patients had increased TAS, SOD and PON1 activity on HDL 2b, but decreased PON1 activity on HDL 3 subclasses. Conclusion: OS is associated with altered lipoprotein subclasses distribution in PCOS patients. Obesity in PCOS affects the profile of HDL subclasses, reflected through the reduced proportion of PON1 activity on HDL 3 subclasses in the presence of sdLDL particles.",
publisher = "Cambridge University Press",
journal = "British Journal of Nutrition",
title = "Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia",
volume = "128",
number = "4",
pages = "604-612",
doi = "10.1017/S0007114521003585"
}

Perović-Blagojević, I., Vekić, J., Macut, Đ., Ignjatović, S., Miljković-Trailović, M., Zeljković, A., Spasojević-Kalimanovska, V., Božić-Antić, I., Bjekić-Macut, J., Kastratović-Kotlica, B., Andrić, Z., Ilić, D.,& Kotur-Stevuljević, J.. (2022). Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia. in British Journal of Nutrition
Cambridge University Press., 128(4), 604-612.
https://doi.org/10.1017/S0007114521003585

Perović-Blagojević I, Vekić J, Macut Đ, Ignjatović S, Miljković-Trailović M, Zeljković A, Spasojević-Kalimanovska V, Božić-Antić I, Bjekić-Macut J, Kastratović-Kotlica B, Andrić Z, Ilić D, Kotur-Stevuljević J. Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia. in British Journal of Nutrition. 2022;128(4):604-612.
doi:10.1017/S0007114521003585 .

Perović-Blagojević, Iva, Vekić, Jelena, Macut, Đuro, Ignjatović, Svetlana, Miljković-Trailović, Milica, Zeljković, Aleksandra, Spasojević-Kalimanovska, Vesna, Božić-Antić, Ivana, Bjekić-Macut, Jelica, Kastratović-Kotlica, Biljana, Andrić, Zoran, Ilić, Dušan, Kotur-Stevuljević, Jelena, "Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia" in British Journal of Nutrition, 128, no. 4 (2022):604-612,
https://doi.org/10.1017/S0007114521003585 . .

TY  - JOUR
AU  - Perović-Blagojević, Iva
AU  - Vekić, Jelena
AU  - Macut, Đuro
AU  - Ignjatović, Svetlana
AU  - Miljković-Trailović, Milica
AU  - Zeljković, Aleksandra
AU  - Spasojević-Kalimanovska, Vesna
AU  - Božić-Antić, Ivana
AU  - Bjekić-Macut, Jelica
AU  - Kastratović-Kotlica, Biljana
AU  - Andrić, Zoran
AU  - Ilić, Dušan
AU  - Kotur-Stevuljević, Jelena
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3974
AB  - Objective: Polycystic ovary syndrome (PCOS) is associated with altered lipid profile and increased small, dense LDL particles (sdLDL). Considering that paraoxonase 1 (PON1) is an anti-oxidative enzyme located on high-density lipoprotein (HDL) particles, the aim of this study was to investigate the connection between oxidative stress (OS) and PON1 activity with lipoprotein subclasses in PCOS depending on obesity. Methods: In 115 PCOS patients lipoprotein subclasses distributions were determined by gradient gel electrophoresis. OS status was assessed by total oxidative status (TOS), advanced oxidation protein products (AOPP), malondialdehyde (MDA), prooxidant-Antioxidant balance (PAB), total antioxidant status (TAS) and superoxide dismutase (SOD) and PON1 activity. Results: Overweight/obese PCOS patients (n=55) had increased OS compared to normal weight patients (n=60). In addition, overweight/obese group had lower HDL size and higher proportion of HDL 3a subclasses (P<0.05). PAB was in negative correlation with HDL 2a (P<0.001), whereas MDA and SOD correlated positively with HDL 3 subclasses (P<0.05). Serum PON1 activity was positively associated with proportions of PON1 activity on HDL 2b (P<0.05) and 2a (P<0.01), but negatively with the proportion on HDL 3 particles (P<0.01). LDL B phenotype patients had increased TAS, SOD and PON1 activity on HDL 2b, but decreased PON1 activity on HDL 3 subclasses. Conclusion: OS is associated with altered lipoprotein subclasses distribution in PCOS patients. Obesity in PCOS affects the profile of HDL subclasses, reflected through the reduced proportion of PON1 activity on HDL 3 subclasses in the presence of sdLDL particles.
PB  - Cambridge University Press
T2  - British Journal of Nutrition
T1  - Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia
DO  - 10.1017/S0007114521003585
ER  - 

@article{
author = "Perović-Blagojević, Iva and Vekić, Jelena and Macut, Đuro and Ignjatović, Svetlana and Miljković-Trailović, Milica and Zeljković, Aleksandra and Spasojević-Kalimanovska, Vesna and Božić-Antić, Ivana and Bjekić-Macut, Jelica and Kastratović-Kotlica, Biljana and Andrić, Zoran and Ilić, Dušan and Kotur-Stevuljević, Jelena",
year = "2021",
abstract = "Objective: Polycystic ovary syndrome (PCOS) is associated with altered lipid profile and increased small, dense LDL particles (sdLDL). Considering that paraoxonase 1 (PON1) is an anti-oxidative enzyme located on high-density lipoprotein (HDL) particles, the aim of this study was to investigate the connection between oxidative stress (OS) and PON1 activity with lipoprotein subclasses in PCOS depending on obesity. Methods: In 115 PCOS patients lipoprotein subclasses distributions were determined by gradient gel electrophoresis. OS status was assessed by total oxidative status (TOS), advanced oxidation protein products (AOPP), malondialdehyde (MDA), prooxidant-Antioxidant balance (PAB), total antioxidant status (TAS) and superoxide dismutase (SOD) and PON1 activity. Results: Overweight/obese PCOS patients (n=55) had increased OS compared to normal weight patients (n=60). In addition, overweight/obese group had lower HDL size and higher proportion of HDL 3a subclasses (P<0.05). PAB was in negative correlation with HDL 2a (P<0.001), whereas MDA and SOD correlated positively with HDL 3 subclasses (P<0.05). Serum PON1 activity was positively associated with proportions of PON1 activity on HDL 2b (P<0.05) and 2a (P<0.01), but negatively with the proportion on HDL 3 particles (P<0.01). LDL B phenotype patients had increased TAS, SOD and PON1 activity on HDL 2b, but decreased PON1 activity on HDL 3 subclasses. Conclusion: OS is associated with altered lipoprotein subclasses distribution in PCOS patients. Obesity in PCOS affects the profile of HDL subclasses, reflected through the reduced proportion of PON1 activity on HDL 3 subclasses in the presence of sdLDL particles.",
publisher = "Cambridge University Press",
journal = "British Journal of Nutrition",
title = "Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia",
doi = "10.1017/S0007114521003585"
}

Perović-Blagojević, I., Vekić, J., Macut, Đ., Ignjatović, S., Miljković-Trailović, M., Zeljković, A., Spasojević-Kalimanovska, V., Božić-Antić, I., Bjekić-Macut, J., Kastratović-Kotlica, B., Andrić, Z., Ilić, D.,& Kotur-Stevuljević, J.. (2021). Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia. in British Journal of Nutrition
Cambridge University Press..
https://doi.org/10.1017/S0007114521003585

Perović-Blagojević I, Vekić J, Macut Đ, Ignjatović S, Miljković-Trailović M, Zeljković A, Spasojević-Kalimanovska V, Božić-Antić I, Bjekić-Macut J, Kastratović-Kotlica B, Andrić Z, Ilić D, Kotur-Stevuljević J. Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia. in British Journal of Nutrition. 2021;.
doi:10.1017/S0007114521003585 .

Perović-Blagojević, Iva, Vekić, Jelena, Macut, Đuro, Ignjatović, Svetlana, Miljković-Trailović, Milica, Zeljković, Aleksandra, Spasojević-Kalimanovska, Vesna, Božić-Antić, Ivana, Bjekić-Macut, Jelica, Kastratović-Kotlica, Biljana, Andrić, Zoran, Ilić, Dušan, Kotur-Stevuljević, Jelena, "Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia" in British Journal of Nutrition (2021),
https://doi.org/10.1017/S0007114521003585 . .

TY  - JOUR
AU  - Perović-Blagojević, Iva
AU  - Ignjatović, Svetlana
AU  - Macut, Djuro
AU  - Kotur-Stevuljević, Jelena
AU  - Bozić-Antić, Ivana
AU  - Vekić, Jelena
AU  - Bjekić-Macut, Jelica
AU  - Kastratović-Kotlica, Biljana
AU  - Andrić, Zoran
AU  - Ilić, Dušan
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3076
AB  - Background: Polycystic ovary syndrome (PCOS) is a cardiornetabolic disorder whose features include dyslipidemia, increased oxidative stress (OS, oxy) and chronic inflammation. The aim of this study was to investigate the ability of a summary score for dyslipidemia, OS and inflammation (the DOI score) to discriminate PCOS patients from healthy individuals and to evaluate the effect of obesity on individual scores and the DOI score in patients. Methods: Lipid status parameters, OS status parameters (advanced oxidation protein products; total oxidative status; prooxidant-antioxidant balance; malondialdehyde; total protein sulphydryl groups and paraoxonase 1 activity) and CRP were measured in 114 patients and 50 controls using standardised assays. The DOI score was calculated as the sum of dyslipidemia, oxy and inflammation scores, determined as Z-score values for every subject in relation to the controls. Results: PCOS patients had significantly higher oxy-score compared to controls (P lt 0.001). In addition, the DOI score was significantly higher in PCOS patients (P lt 0.001) as the dyslipidemia (P lt 0.05) and inflammatory scores (P lt 0.001) were greater. According to ROC analysis, the oxy-score showed better diagnostic accuracy in discriminating PCOS patients compared to the DOI score (AUC>0.9, P lt 0.01). Furthermore, obesity affected the risk scores in patients, especially the DOI score (significantly higher DOI scores in such patients, P  lt 0.001). Conclusion: PCOS patients had greater dyslipidemia, chronic inflammation and OS compared to controls and could be segregated using all four scores. Our data suggest that weight gain could be the common factor responsible for induction and propagation of dyslipidemia, OS and inflammation in PCOS patients.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (The Doi Score) in Women with Polycystic Ovary Syndrome and its Relationship with Obesity
VL  - 37
IS  - 4
SP  - 476
EP  - 485
DO  - 10.2478/jomb-2018-0008
ER  - 

@article{
author = "Perović-Blagojević, Iva and Ignjatović, Svetlana and Macut, Djuro and Kotur-Stevuljević, Jelena and Bozić-Antić, Ivana and Vekić, Jelena and Bjekić-Macut, Jelica and Kastratović-Kotlica, Biljana and Andrić, Zoran and Ilić, Dušan",
year = "2018",
abstract = "Background: Polycystic ovary syndrome (PCOS) is a cardiornetabolic disorder whose features include dyslipidemia, increased oxidative stress (OS, oxy) and chronic inflammation. The aim of this study was to investigate the ability of a summary score for dyslipidemia, OS and inflammation (the DOI score) to discriminate PCOS patients from healthy individuals and to evaluate the effect of obesity on individual scores and the DOI score in patients. Methods: Lipid status parameters, OS status parameters (advanced oxidation protein products; total oxidative status; prooxidant-antioxidant balance; malondialdehyde; total protein sulphydryl groups and paraoxonase 1 activity) and CRP were measured in 114 patients and 50 controls using standardised assays. The DOI score was calculated as the sum of dyslipidemia, oxy and inflammation scores, determined as Z-score values for every subject in relation to the controls. Results: PCOS patients had significantly higher oxy-score compared to controls (P lt 0.001). In addition, the DOI score was significantly higher in PCOS patients (P lt 0.001) as the dyslipidemia (P lt 0.05) and inflammatory scores (P lt 0.001) were greater. According to ROC analysis, the oxy-score showed better diagnostic accuracy in discriminating PCOS patients compared to the DOI score (AUC>0.9, P lt 0.01). Furthermore, obesity affected the risk scores in patients, especially the DOI score (significantly higher DOI scores in such patients, P  lt 0.001). Conclusion: PCOS patients had greater dyslipidemia, chronic inflammation and OS compared to controls and could be segregated using all four scores. Our data suggest that weight gain could be the common factor responsible for induction and propagation of dyslipidemia, OS and inflammation in PCOS patients.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (The Doi Score) in Women with Polycystic Ovary Syndrome and its Relationship with Obesity",
volume = "37",
number = "4",
pages = "476-485",
doi = "10.2478/jomb-2018-0008"
}

Perović-Blagojević, I., Ignjatović, S., Macut, D., Kotur-Stevuljević, J., Bozić-Antić, I., Vekić, J., Bjekić-Macut, J., Kastratović-Kotlica, B., Andrić, Z.,& Ilić, D.. (2018). Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (The Doi Score) in Women with Polycystic Ovary Syndrome and its Relationship with Obesity. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 37(4), 476-485.
https://doi.org/10.2478/jomb-2018-0008

Perović-Blagojević I, Ignjatović S, Macut D, Kotur-Stevuljević J, Bozić-Antić I, Vekić J, Bjekić-Macut J, Kastratović-Kotlica B, Andrić Z, Ilić D. Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (The Doi Score) in Women with Polycystic Ovary Syndrome and its Relationship with Obesity. in Journal of Medical Biochemistry. 2018;37(4):476-485.
doi:10.2478/jomb-2018-0008 .

Perović-Blagojević, Iva, Ignjatović, Svetlana, Macut, Djuro, Kotur-Stevuljević, Jelena, Bozić-Antić, Ivana, Vekić, Jelena, Bjekić-Macut, Jelica, Kastratović-Kotlica, Biljana, Andrić, Zoran, Ilić, Dušan, "Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (The Doi Score) in Women with Polycystic Ovary Syndrome and its Relationship with Obesity" in Journal of Medical Biochemistry, 37, no. 4 (2018):476-485,
https://doi.org/10.2478/jomb-2018-0008 . .